PDL BioPharma, Inc.
PDLIV
NASDAQ
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
| 08/31/2020 | 06/30/2020 | 03/31/2020 | 12/31/2019 | 09/30/2019 | |
|---|---|---|---|---|---|
| Net Income | -- | -57.52% | 42.20% | -208.64% | -302.44% |
| Total Depreciation and Amortization | -- | -11.85% | -5.95% | -5.28% | -9.47% |
| Total Amortization of Deferred Charges | -- | -26.79% | -80.84% | -23.11% | -2.71% |
| Total Other Non-Cash Items | -- | 44.94% | -24.86% | 1,452.06% | 119.12% |
| Change in Net Operating Assets | -- | 67.18% | -254.28% | -167.45% | 425.51% |
| Cash from Operations | -- | 31.31% | 0.66% | -273.63% | 59.62% |
| Capital Expenditure | -- | -52.69% | 64.09% | 24.05% | -181.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -16.01% | -35.33% | -31.35% | 173.48% |
| Cash from Investing | -- | -16.48% | -34.97% | -31.43% | 172.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 80.75% | -1,213.77% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -4.80% | -74.67% | -137.99% | 82.86% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -146.41% | 276.15% | -- |
| Cash from Financing | -- | 52.09% | 59.87% | -549.32% | 41.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 53.90% | 53.74% | -1,180.71% | 111.46% |